IMMX News and Press, Immix Biopharma Inc. From 02/01/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short-squeeze stocks continue to be hot with traders and we’re going over five candidates that investors will want to watch today. Source: Alextype/Shutterstock.com Today’s list of short-squeeze candid...

LOS ANGELES, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today a...

Manufactured IMX-110 to be utilized in both clinical trials: 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors An image of ...

3 Penny Stocks That Are Climbing During Today’s Trading Session After a week or so of less than stellar trading patterns for penny stocks and blue chips, today is a better day in the stock market. By mid-day trading, the S&P 500 pushed up by around 550 points, presenting a si...

IMX-110 + anti-PD-1 produced 63-day median survival in a genetic (KPC) pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune system Historically, 42-days is the median survival produced by a 4-drug combination of 2 chemotherapies and...

100% of patients treated with IMX-110 completed planned treatment cycles without drug-related interruptions in its ongoing Phase 1b/2a clinical trial IMX-110 is in clinical development as a monotherapy for soft tissue sarcoma (STS), a $3 billion market expected to grow to $6.5 billion...

3 Penny Stocks to Add to Your Watchlist Today With stock market futures eyeing a more positive trading day for penny stocks and blue chips, investors are excited about the near future. In the past few weeks, trading has been extremely volatile across the board. This is the result of the...

IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line-therapy-resistant cancer - soft tissue sarcoma (STS) mice study IMX-110 response rate surpassed standard of care doxorubicin’s response rate of 0% after 1 cycle of treatment in the sa...

Los Angeles, CA, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx) TM targeting oncology and immuno-dysregulated diseases, today ann...

2021 was a year to be easily forgotten for biotech stocks. The S&P 500 climbed 26.9%. However, SPDR S&P Biotech exchange-traded fund dropped 20.5%. Looks like 2022 will be “THE” year for biotech sector. In a recent note from Piper Sandler analyst Christopher Raymond and ...